Ou: a cadeia que nasceu de uma sentença Since August 4th, ANVISA (Brazilian Health Regulatory Agency) has been receiving requests for Special Authorization from companies interested in cultivating Cannabis sativa in Brazil for medicinal purposes. This date marks the operational start of a new production chain, but news reports still primarily treat the issue as another step in the regulation of cannabis. The most interesting aspect lies elsewhere: the timeline for medicinal c

In the first half of 2026, pharmaceutical and artificial intelligence companies announced fourteen major deals totaling at least US$23.6 billion in potential value, according to a survey by analyst Oliver Sprague Kelly. The prevailing interpretation was that the pharmaceutical industry is betting heavily on radical innovation . I spent a good part of my twenty-five years in the industry in environments where such agreements are discussed and approved, and those who have lived

Technological innovation is a fundamental factor for a country’s economic development and competitiveness. In Brazil, intellectual...

Health innovation and the remarkable growth of the pharmaceutical sector—with a projected global revenue of USD 1.155 trillion in...